Ryder, Robert EJ, City Hospital, Birmingham, UK

• British Journal of Diabetes Vol. 15 No. 2 (2015) - Editorials
  Rehabilitation of pioglitazone
  Abstract  HTML  PDF
• British Journal of Diabetes Vol. 15 No. 4 (2015) - Editorials
  Diabetes medications with cardiovascular protection in the wake of EMPA-REG OUTCOME: the optimal combination may be metformin, pioglitazone and empagliflozin
  Abstract  HTML  PDF
• British Journal of Diabetes Vol. 16 No. 2 (2016) - Meeting Reports
  This house believes that sulphonylureas should not be used routinely as second-line treatments for patients with type 2 diabetes
  Abstract  HTML  PDF
• British Journal of Diabetes Vol. 16 No. 3 (2016) - Editorials
  Diabetes medications with cardiovascular protection – what now after LEADER®? Could metformin, pioglitazone, empagliflozin and liraglutide complement each other to save lives?
  Abstract  HTML  PDF
• British Journal of Diabetes Vol. 17 No. 3 (2017) - Editorials
  What now on the CANVAS of diabetes medications with cardiovascular protection? Could metformin, pioglitazone, SGLT2 inhibitors and liraglutide complement each other to save lives?
  Abstract  HTML  PDF
• British Journal of Diabetes Vol. 20 No. 2 (2020): December 2020 - Editorials
  Diabetes medications with cardiovascular protection: the likelihood of benefit from combination therapy increases further following new evidence during 2020
  Abstract  PDF  HTML